日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Using AI-generated digital twins to boost clinical trial efficiency in Alzheimer's disease

利用人工智能生成的数字孪生体提高阿尔茨海默病临床试验效率

Wang, Deli; Florian, Hana; Lynch, Shau-Yu; Robieson, Weining; Zhuang, Run; Kusiak, Coco; Ross, Jessica L; Walsh, Jonathan R; Graff, Ole

Decision making in clinical trials: Interim analyses, innovative design, and biomarkers

临床试验中的决策:中期分析、创新设计和生物标志物

Welsh-Bohmer, Kathleen A; Kerchner, Geoffrey A; Dhadda, Shobha; Garcia, Miguel; Miller, David S; Natanegara, Fanni; Raket, Lars Lau; Robieson, Weining; Siemers, Eric R; Carrillo, Maria C; Weber, Christopher J

Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study

帕金森病患者持续皮下注射左旋多巴/磷酸卡比多巴:一项为期12个月的单臂、开放标签3期研究的安全性和有效性结果

Aldred, Jason; Freire-Alvarez, Eric; Amelin, Alexander V; Antonini, Angelo; Bergmans, Bruno; Bergquist, Filip; Bouchard, Manon; Budur, Kumar; Carroll, Camille; Chaudhuri, K Ray; Criswell, Susan R; Danielsen, Erik H; Gandor, Florin; Jia, Jia; Kimber, Thomas E; Mochizuki, Hideki; Robieson, Weining Z; Spiegel, Amy M; Standaert, David G; Talapala, Saritha; Facheris, Maurizio F; Fung, Victor S C

Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study

更正:帕金森病患者持续皮下注射左旋多巴/磷酸卡比多巴:一项为期 12 个月的单臂、开放标签 3 期研究的安全性和有效性结果

Aldred, Jason; Freire-Alvarez, Eric; Amelin, Alexander V; Antonini, Angelo; Bergmans, Bruno; Bergquist, Filip; Bouchard, Manon; Budur, Kumar; Carroll, Camille; Chaudhuri, K Ray; Criswell, Susan R; Danielsen, Erik H; Gandor, Florin; Jia, Jia; Kimber, Thomas E; Mochizuki, Hideki; Robieson, Weining Z; Spiegel, Amy M; Standaert, David G; Talapala, Saritha; Facheris, Maurizio F; Fung, Victor S C

DUOGLOBE: One-Year Outcomes in a Real-World Study of Levodopa Carbidopa Intestinal Gel for Parkinson's Disease

DUOGLOBE:左旋多巴卡比多巴肠凝胶治疗帕金森病真实世界研究的一年结果

Standaert, David G; Aldred, Jason; Anca-Herschkovitsch, Marieta; Bourgeois, Paul; Cubo, Esther; Davis, Thomas L; Iansek, Robert; Kovács, Norbert; Pontieri, Francesco E; Siddiqui, Mustafa S; Simu, Mihaela; Bergmann, Lars; Kukreja, Pavnit; Robieson, Weining Z; Chaudhuri, K Ray

Modified reference based imputation and tipping point analysis in the presence of missing data due to COVID-19

针对因 COVID-19 导致的数据缺失,改进的基于参考值的插补和临界点分析

Jin, Man; Liu, Ran; Robieson, Weining

Predictors of Response for "Off" Time Improvement With Levodopa-Carbidopa Intestinal Gel Treatment: An Analysis of the GLORIA Registry

左旋多巴-卡比多巴肠凝胶治疗改善“关期”反应的预测因素:GLORIA注册研究分析

Poewe, Werner; Bergmann, Lars; Robieson, Weining Z; Antonini, Angelo

A post hoc comparison of levodopa-carbidopa intestinal gel daytime monotherapy vs polytherapy safety and efficacy in patients with advanced Parkinson's disease: Results from 6 phase 3/3b open-label studies

一项事后比较左旋多巴-卡比多巴肠凝胶日间单药治疗与联合治疗在晚期帕金森病患者中的安全性和有效性的研究:来自 6 项 3/3b 期开放标签研究的结果

Boyd, James T; Zadikoff, Cindy; Benesh, Janet A; Zamudio, Jorge; Robieson, Weining Z; Kukreja, Pavnit; Yokoyama, Masayuki; Siddiqui, Mustafa S

Burden of non-motor symptoms in Parkinson's disease patients predicts improvement in quality of life during treatment with levodopa-carbidopa intestinal gel

帕金森病患者非运动症状的负担可预测左旋多巴-卡比多巴肠凝胶治疗期间生活质量的改善。

Ray Chaudhuri, K; Antonini, A; Robieson, W Z; Sanchez-Soliño, O; Bergmann, L; Poewe, W

Systematic evaluation of levodopa-carbidopa intestinal gel patient-responder characteristics

系统评价左旋多巴-卡比多巴肠凝胶患者反应特征

Standaert, David G; Boyd, James T; Odin, Per; Robieson, Weining Z; Zamudio, Jorge; Chatamra, Krai